Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia 53Lymphoma 51Melanoma 44Breast Neoplasms 37Lymphoma, Follicular 36Leukemia, Myeloid, Acute 33Leukemia, Lymphocytic, Chronic, B-Cell 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Lymphoma, Non-Hodgkin 29Neuroblastoma 28Multiple Myeloma 28Lymphoma, Large B-Cell, Diffuse 25Prostatic Neoplasms 23Lymphoma, Mantle-Cell 23Myelodysplastic Syndromes 22Lymphoma, Large-Cell, Immunoblastic 20Neoplasms, Plasma Cell 19Leukemia, Myeloid, Chronic-Phase 19Hodgkin Disease 18Carcinoma, Non-Small-Cell Lung 18Burkitt Lymphoma 18Ovarian Neoplasms 17Lymphoma, B-Cell, Marginal Zone 17Lung Neoplasms 17Neoplasm Metastasis 16Glioblastoma 16Leukemia, Myelogenous, Chronic, BCR-ABL Positive 15Congenital Abnormalities 15Leukemia, Myeloid, Accelerated Phase 14Gliosarcoma 12

Interventions

Nivolumab 20Ipilimumab 10Paclitaxel 7linrodostat 6Standard of Care 6Sirolimus 5Gemcitabine 5Bevacizumab 5temsirolimus 4relatlimab 4Pemetrexed 4Docetaxel 4Carboplatin 4ARRY-334543 4Vorinostat 3Erlotinib Hydrochloride 3Dasatinib 3Cetuximab 3regorafenib 2olaparib 2apatinib 2anlotinib 2abemaciclib 2Trastuzumab 2Surveys and Questionnaires 2Sunitinib 2Sorafenib 2Olanzapine 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2Magnetic Resonance Spectroscopy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Cancer × sargramostim × Clear all
NCT02383212 2020-01-27

Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies

Regeneron Pharmaceuticals

Phase 1 Completed
398 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡